biosciences

Breakthrough Trial Results in Rare Bone Cancer Inhibrx’s lead drug, ozekibart, achieved a landmark win in its ChonDRAgon trial for advanced conventional chondrosarcoma. This rare bone cancer has no approved systemic therapies,